IRIS
PANICHELLA, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.643
NA - Nord America 3.561
EU - Europa 3.275
SA - Sud America 758
AF - Africa 96
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.342
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.322
SG - Singapore 1.356
IT - Italia 1.279
CN - Cina 938
RU - Federazione Russa 859
BR - Brasile 589
VN - Vietnam 458
BD - Bangladesh 233
HK - Hong Kong 205
GB - Regno Unito 170
DE - Germania 159
IE - Irlanda 159
NL - Olanda 158
CA - Canada 137
FR - Francia 116
FI - Finlandia 111
IN - India 83
TR - Turchia 76
MX - Messico 64
PL - Polonia 64
AR - Argentina 63
PK - Pakistan 46
IQ - Iraq 36
ES - Italia 35
EC - Ecuador 34
ID - Indonesia 34
ZA - Sudafrica 34
IL - Israele 32
JP - Giappone 30
SE - Svezia 30
AT - Austria 27
CO - Colombia 24
UZ - Uzbekistan 21
UA - Ucraina 19
MA - Marocco 17
CH - Svizzera 15
EG - Egitto 14
LT - Lituania 13
VE - Venezuela 13
BE - Belgio 12
CL - Cile 12
PH - Filippine 11
AE - Emirati Arabi Uniti 10
SA - Arabia Saudita 10
MY - Malesia 9
RO - Romania 9
KE - Kenya 8
PY - Paraguay 8
HN - Honduras 7
KR - Corea 7
PE - Perù 7
TN - Tunisia 7
AU - Australia 6
DZ - Algeria 5
JO - Giordania 5
KZ - Kazakistan 5
OM - Oman 5
BY - Bielorussia 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GR - Grecia 4
GT - Guatemala 4
JM - Giamaica 4
NP - Nepal 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
CG - Congo 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
KW - Kuwait 3
NI - Nicaragua 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
HR - Croazia 2
IR - Iran 2
KH - Cambogia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
PS - Palestinian Territory 2
QA - Qatar 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AD - Andorra 1
AG - Antigua e Barbuda 1
BB - Barbados 1
BH - Bahrain 1
CU - Cuba 1
CV - Capo Verde 1
DM - Dominica 1
EE - Estonia 1
Totale 11.322
Salva come PNG Salva come JPEG
Città #
Dallas 820
Singapore 743
San Jose 384
Ashburn 383
Beijing 330
Hong Kong 195
Moscow 159
Dublin 156
Ho Chi Minh City 153
Los Angeles 143
New York 120
Milan 118
Hanoi 102
Rome 85
Helsinki 74
Santa Clara 69
São Paulo 65
The Dalles 65
Pisa 64
Chandler 60
Hefei 54
Lauterbourg 54
Warsaw 54
Munich 52
Council Bluffs 51
Florence 50
Istanbul 47
Montreal 44
London 40
Orem 40
Amsterdam 37
Da Nang 34
Mexico City 34
Naples 33
Bologna 32
Frankfurt am Main 32
Boardman 31
Chicago 31
Genoa 31
Beauharnois 29
Buffalo 27
Lucca 27
Tokyo 27
Brooklyn 26
Poplar 26
Rio de Janeiro 26
Stockholm 25
Tel Aviv 25
Atlanta 24
Boston 24
Lappeenranta 24
Turin 24
Johannesburg 23
Nuremberg 23
Chennai 22
Denver 21
Seattle 20
Toronto 20
Livorno 19
Brescia 18
Mumbai 17
Tashkent 17
Belo Horizonte 15
Haiphong 15
Lahore 15
Phoenix 15
Guayaquil 14
Manchester 14
Washington 14
Biên Hòa 13
Shenzhen 13
Assago 12
Bari 12
Charlotte 12
Curitiba 12
Paris 12
Quito 12
Turku 12
Dhaka 11
Houston 11
Palermo 11
Querétaro 11
Redondo Beach 11
Baghdad 10
Cambridge 10
Guangzhou 10
Ottawa 10
San Mateo 10
Vienna 10
Brasília 9
Hangzhou 9
Portsmouth 9
San Francisco 9
Suzhou 9
Verona 9
Zhengzhou 9
Ankara 8
Buti 8
City of London 8
Dongguan 8
Totale 6.025
Salva come PNG Salva come JPEG
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 592
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 422
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 319
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 319
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 295
Screening the health status of people working in a university 287
Eligibility for vericiguat in a real‐world, contemporary heart failure population 283
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 276
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 273
Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population 260
RNA-targeting and gene editing therapies for transthyretin amyloidosis 250
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 244
Role of Imaging in Cardiomyopathies 235
Valvular heart disease in patients with cardiac amyloidosis 235
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 220
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 217
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 210
Assessing cardiac mechanics through left ventricular haemodynamic forces 208
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 205
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 205
Subclinical cardiac damage in cancer patients before chemotherapy 205
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 204
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review 204
Cardiac Amyloidosis: How Its Epidemiology is Changing 202
The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population 200
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 196
Bridging Atrial and Ventricular Failure Through Biomarkers 195
Sex-related differences in ventricular remodeling after myocardial infarction 194
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 192
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 187
Sex differences in transthyretin cardiac amyloidosis 181
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 178
Pathophysiology of Cardiac Amyloidosis 176
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 174
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers 174
Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review 172
High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis 170
Echocardiographic Estimate of Pulmonary Capillary Wedge Pressure Improves Outcome Prediction in Heart Failure Patients with Reduced and Mildly Reduced Ejection Fraction 168
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 167
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity 164
Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat 157
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 156
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 154
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis 151
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 144
Metabolomics to predict heart failure development: A new frontier? 140
Dissecting the heart failure phenotype through phenomics 139
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 136
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 121
Pirfenidone as a novel cardiac protective treatment 121
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management 118
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond 116
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 109
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up 108
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy 91
Changes in CMR-derived ventricular strain, fibrosis progression and outcomes in hypertrophic cardiomyopathy 60
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 44
The evolving role of metabolic and bariatric surgery in contemporary clinical practice 30
null 29
PAWP vs LVEDP During Invasive Cardiopulmonary Exercise Testing: In Search of the Holy Grail of a Hemodynamic Truth in Heart Failure. 25
Therapy of amyloidosis: stabilizers and silencers 9
Totale 11.416
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.950
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.950
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202266 0 0 0 5 7 7 10 17 7 6 2 5
2022/2023367 5 28 10 21 44 40 14 47 109 10 27 12
2023/2024333 13 11 63 36 7 25 27 13 15 26 28 69
2024/20252.806 71 68 134 108 184 154 383 539 286 175 378 326
2025/20267.844 441 1.077 771 1.145 801 561 747 477 549 544 588 143
Totale 11.416